DPP4 and diabetes mellitus: Interestingly, multiple analyses from independent retrospective observational studies reported significant improvement in severe outcomes and mortality among patients with COVID-19 and type 2 diabetes mellitus (T2DM) using a DPP4 inhibitor [9,10,11].